| dc.creator | Sánchez-Recillas, Amanda | |
| dc.creator | Araujo-León, Jesus A. | |
| dc.creator | Rivero-Medina, Laura | |
| dc.creator | Moreno-Diaz, Hermenegilda | |
| dc.creator | Antonio- de la Cruz, Ana S. | |
| dc.creator | Ortiz-Andrade, Rolffy | |
| dc.date | 2018-12-01 | |
| dc.date.accessioned | 2020-08-04T16:41:49Z | |
| dc.date.available | 2020-08-04T16:41:49Z | |
| dc.identifier | http://www.revistas.usach.cl/ojs/index.php/blacpma/article/view/3502 | |
| dc.identifier.uri | https://revistaschilenas.uchile.cl/handle/2250/147971 | |
| dc.description | The aim of current study was to determinate ex vivo and chromatographic fingerprint by HPLC of four extracts of Euphorbia furcillata K. Ethyl acetate extract of Euphorbia furcillata (EaEEf) was the most effective and potent extract (Emax=98.69±1.24%) and its effect was partially endothelium-dependent. Functional vasorelaxant mechanism of action of EaEEf was determinate, EaEEf showed efficient relaxation of KCl [80 mM]-induced contraction and norepinephrine and CaCl2 contraction curves showed diminution of maximal contraction in the presence of EAEEf and EaEEf-relaxation curve was shifted to the right in the presence of L-NAME (nitric oxide synthase inhibitor) and ODQ (guanylate cyclase inhibitor). Chromatographic fingerprints analysis suggests presence of diterpenoid such as abietane, tigliane, and ingenane skeletons. Our experiments suggest the EaEEf vasorelaxant activity could be attributed to diterpenoid molecules whose mechanism involves nitric oxide production and calcium channel blockade. | es-ES |
| dc.format | application/pdf | |
| dc.language | spa | |
| dc.publisher | Universidad de Santiago de Chile | es-ES |
| dc.relation | http://www.revistas.usach.cl/ojs/index.php/blacpma/article/view/3502/26002817 | |
| dc.source | Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas; Vol 17, No 3: BLACPMA, Mayo 2018; 310 - 323 | es-ES |
| dc.source | 0717-7917 | |
| dc.title | Vasorelaxant activity of Euphorbia furcillata Kunth mainly by activation of NO/cGMP pathway and calcium channel blockade | es-ES |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
